Sign In  |  Register  |  About Walnut Creek Guide  |  Contact Us

Walnut Creek, CA
September 01, 2020 1:43pm
7-Day Forecast | Traffic

  • Search Hotels in Walnut Creek Guide

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

ADC Therapeutics SA Common Shares (NY: ADCT )

1.960 -0.160 (-7.55%)
Official Closing Price Updated: 7:00 PM EST, Dec 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ADC Therapeutics SA Common Shares

< Previous 1 2 3 4 5 6 7 8 Next >
TSMC, CommScope Holding And Other Big Stocks Moving Higher On Thursday
U.S. stocks traded higher, with the Dow Jones gaining around 150 points on Thursday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
ADC Therapeutics to Participate in the 41st Annual J.P. Morgan Healthcare Conference
From ADC Therapeutics SA
Via Business Wire
4 Analysts Have This to Say About ADC Therapeutics
Via Benzinga
ADC Therapeutics Appoints Mohamed Zaki as Chief Medical Officer
From ADC Therapeutics SA
Via Business Wire
Analyst Ratings for ADC Therapeutics
Analysts have provided the following ratings for ADC Therapeutics (NYSE:ADCT) within the last quarter: 
Via Benzinga
Analyst Ratings for ADC Therapeutics
Analysts have provided the following ratings for ADC Therapeutics (NYSE:ADCT) within the last quarter: 
Via Benzinga
Expert Ratings for ADC Therapeutics
ADC Therapeutics (NYSE:ADCT) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Nike, FedEx And Some Other Big Stocks Moving Higher In Today's Pre-Market Session
U.S. stock futures traded higher this morning. Here are some big stocks recording gains in today’s pre-market trading session. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
We're starting off the day with a breakdown of the biggest pre-market stock movers traders need to know about on Wednesday 
Via InvestorPlace
Why Core Scientific Shares Are Trading Lower By Around 32%; Here Are 26 Stocks Moving Premarket
Gainers ADC Therapeutics SA (NASDAQ: ADCT) shares rose 36.8% to $4.35 in pre-market trading. ADC Therapeutics and Sobi announced European Commission approval of ZYNLONTA for the treatment of relapsed... 
Via Benzinga
ADC Therapeutics and Sobi Announce European Commission Approval of ZYNLONTA® (loncastuximab tesirine) for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
From ADC Therapeutics SA
Via Business Wire
ADC Therapeutics Appoints Jose Carmona as Chief Financial Officer
From ADC Therapeutics SA
Via Business Wire
Week In Review: Full-Life Acquires Focus-X And Its Eight Radiotherapeutics In $245 Million Deal
Full-Life Technologies, a Brussels-Shanghai radiotherapeutics company, will acquire Focus-X Therapeutics for up to $245 million. Using its proprietary peptide engineering technology, Focus-X has built... 
Via Talk Markets
Biocytogen Enters into Antibody Agreement with ADC Therapeutics
From Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Via Business Wire
Stocks That Hit 52-Week Lows On Monday
  On Monday, 79 companies reached new 52-week lows. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 9, 2022
Upgrades 
Via Benzinga
ADC Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates
From ADC Therapeutics SA
Via Business Wire
ADC Therapeutics to Participate in the Jefferies London Healthcare Conference
From ADC Therapeutics SA
Via Business Wire
ADC Therapeutics Announces Abstracts Accepted for Presentation at the 64th ASH Annual Meeting
From ADC Therapeutics SA
Via Business Wire
IGM Biosciences and ADC Therapeutics Announce Clinical Collaboration Agreement to Evaluate Imvotamab (IGM-2323) in Combination with ZYNLONTA® in Patients with Relapsed or Refractory B Cell Non-Hodgkin’s Lymphoma
From ADC Therapeutics SA
Via Business Wire
IGM Biosciences and ADC Therapeutics Announce Clinical Collaboration Agreement to Evaluate Imvotamab (IGM-2323) in Combination with ZYNLONTA® in Patients with Relapsed or Refractory B Cell Non-Hodgkin’s Lymphoma
From IGM Biosciences, Inc.
Via GlobeNewswire
ADC Therapeutics Appoints Kristen Harrington-Smith as Chief Commercial Officer and Peter Graham as Chief Legal Officer
From ADC Therapeutics SA
Via Business Wire
ADC Therapeutics to Host Third Quarter 2022 Financial Results Conference Call on November 8, 2022
From ADC Therapeutics SA
Via Business Wire
ADC Therapeutics Announces Abstracts to be Presented at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2022)
From ADC Therapeutics SA
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For September 21, 2022
Upgrades For Berkshire Hathaway Inc (NYSE:BRK), Edward Jones upgraded the previous rating of Hold to Buy. Berkshire Hathaway earned $6312.49 in the second quarter, compared to $4399.91 in the year-ago... 
Via Benzinga
ADC Therapeutics and Sobi Announce ZYNLONTA® (loncastuximab tesirine) Receives Positive CHMP Opinion in Europe for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
From ADC Therapeutics SA
Via Business Wire
INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in ADC Therapeutics SA with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in ADC Therapeutics SA with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2022
Upgrades 
Via Benzinga
Where ADC Therapeutics Stands With Analysts
Over the past 3 months, 4 analysts have published their opinion on ADC Therapeutics (NYSE:ADCT) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 WalnutCreekGuide.com & California Media Partners, LLC. All rights reserved.